Massachusetts Biotech Advances Novel Cytokine TherapiesNov 16, 2023-Source: Dr. Robert Driscoll (11/15/23) Wedbush sees over 300% upside for Werewolf stock based on early clinical success for its PREDATOR platform and… ...
Telehealth Co. Signs Largest Client YetMar 30, 2023-Source: Streetwise Reports (3/30/23) Onboarding will begin in April for the health care system that has more than 1,200 care centers in seven… ...
Biopharma Co.’s Burn Tissue Removal Product ApprovedJan 6, 2023-Source: Swayampakula Ramakanth (1/4/23) Because of the green light from the U.S. Food and Drug Administration, H.C. Wainwright & Co. raised its target… ...
Biotech at Good Entry Point for Investors, Analyst SaysDec 21, 2022-Source: Andrew Partheniou (12/20/22) The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more than the CA$10 million the market… ...
Why One Fund Owns 13% of This Small-Cap PharmaDec 14, 2022-Source: Streetwise Reports (12/12/22) Clinical-stage Algernon Pharmaceuticals' multiple pipelines include testing a psychedelic for the treatment of stroke, and testing other drugs for… ...
Biotech Co.’s Shares Soar to New 52-Week HighDec 8, 2022-Source: Streetwise Reports (12/7/22) Prometheus Biosciences Inc. shares traded 170% higher to a new 52-week intraday high after the company reported positive results… ...
Expert Says Health Tech Co. Is in Another Buy SpotDec 1, 2022-Source: Clive Maund (11/30/22) Expert Clive Maund reviews the 1-year chart for Reliq Health Technologies to tell you why he believes it is… ...
Biopharma Co. Trades to New 52-Week HighNov 29, 2022-Source: Streetwise Reports (11/28/22) Shares of Axsome Therapeutics Inc. traded to a new 52-week high after the company reported its AXS-05 successfully met… ...
US Biopharma Co. Is Attractive, Derisked Investment, Analyst SaysNov 14, 2022-Source: Streetwise Reports (11/11/22) With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration… ...
Expert Says Buy Pharma Co. Stock ‘as Soon as Possible’Oct 28, 2022-Source: Clive Maund (10/25/22) Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light… ...
Biopharma Co.’s Shares Roll to New 52-Week High PriceOct 14, 2022-Source: Streetwise Reports (10/12/22) Shares of DICE Therapeutics Inc. traded 62% higher yesterday and established a new 52-week intraday high after the company… ...
Biopharma Co. Partners With Merck for Combo Drug TrialOct 13, 2022-Source: Dr. Joseph Pantginis (10/12/22) With this and other clinical studies, the U.S. company has a busy and, thus, catalyst-rich Q4/22 ahead, noted… ...
Trial Results Show New Drug Improves Dry Eye SymptomsJul 20, 2022-These study data from Aldeyra Therapeutics Inc. solidified the therapeutic's path to filing a new drug application, potentially in Q3/22, noted an… ...
Biopharma Co. Posts 17% BMI Reduction in Ph. 2 TrialJul 18, 2022-Source: Streetwise Reports 07/14/2022 Shares of Rhythm Pharmaceuticals Inc. rose by over 30% after the company posted positive interim results from its… ...
Results of Dermatitis Clinical Trial Due This SummerJun 23, 2022-Enrollment is now done for VYNE Therapeutics Inc.'s Phase 2a trial following encouraging Phase 1b efficacy data, noted an H.C. Wainwright &… ...
New Positive Data Seem to Support Drug Label ExpansionJun 23, 2022-Checkpoint Therapeutics Inc., the biopharma behind this late-stage monoclonal antibody for metastatic cutaneous squamous cell carcinoma, could use the new trial results… ...